Growth Metrics

Trinity Biotech (TRIB) Short-Term Debt repayments (2021 - 2024)

Trinity Biotech's Short-Term Debt repayments history spans 4 years, with the latest figure at -$665000.0 for Q4 2024.

  • On a quarterly basis, Short-Term Debt repayments fell 19.18% to -$665000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was -$2.4 million, a 0.79% increase, with the full-year FY2024 number at -$2.5 million, up 75.09% from a year prior.
  • Short-Term Debt repayments hit -$665000.0 in Q4 2024 for Trinity Biotech, down from -$558000.0 in the prior quarter.
  • Over the last five years, Short-Term Debt repayments for TRIB hit a ceiling of -$743.0 in Q2 2021 and a floor of -$741000.0 in Q4 2021.
  • Historically, Short-Term Debt repayments has averaged -$478905.4 across 4 years, with a median of -$574000.0 in 2022.
  • The widest YoY moves for Short-Term Debt repayments: up 22.13% in 2022, down 4543.34% in 2022.
  • Tracing TRIB's Short-Term Debt repayments over 4 years: stood at -$741000.0 in 2021, then increased by 22.13% to -$577000.0 in 2022, then rose by 3.29% to -$558000.0 in 2023, then dropped by 19.18% to -$665000.0 in 2024.
  • Business Quant data shows Short-Term Debt repayments for TRIB at -$665000.0 in Q4 2024, -$558000.0 in Q4 2023, and -$571000.0 in Q3 2023.